Gerald Maloney, DO, FAAEM, is an attending emergency physician and toxicologist at MetroHealth Medical Center in Cleveland, a flight physician with Metro LifeFlight also in Cleveland ; and a major in the U.S. Army Reserve. He's a senior instructor in Emergency Medicine at Case Western Reserve University. Before receiving his medical degree from the University of New England in Biddeford, Maine, he was a paramedic with Cataldo Ambulance Service in Massachusetts.

We believe that we will need to recruit additional management and technical personnel. There is currently a shortage of, and intense competition for, skilled executives and employees with relevant scientific and technical expertise, and this shortage is likely to continue. The inability to attract and retain sufficient scientific, technical and managerial personnel could limit or delay our product development efforts, which would reduce our ability to successfully commercialize product candidates and our business. We expect to expand our operations, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. We expect to have significant growth in the scope of our operations as our product candidates are commercialized. To manage our anticipated future growth, we must implement and improve our managerial, operational and financial systems, expand facilities and recruit and train additional qualified personnel. Due to our limited resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert management and business development resources. Any inability to manage growth could delay the execution of our business strategy or disrupt our operations. Our competitors may develop and market drugs that are less expensive, safer, or more effective, which may diminish or eliminate the commercial success of any of our product candidates. The biotechnology and pharmaceutical industries are highly competitive and characterized by rapid technological change. Because we anticipate that our research approach will integrate many technologies, it may be difficult for us to stay abreast of the rapid changes in technology. If we fail to stay at the forefront of technological change, we will be unable to compete effectively. Our competitors may render our technologies obsolete by advances in existing technological approaches or the development of different approaches by one or more of our current or future competitors. We will compete with Pfizer and Endo in the treatment of neuropathic pain; Purdue Pharmaceuticals, Johnson & Johnson and Endo in the treatment of post-operative pain; and Johnson & Johnson and others in the treatment of back pain. There are also many companies, both publicly and privately held, including well-known pharmaceutical companies and academic and other research institutions, engaged in developing pharmaceutical products for the treatment of life-threatening cancers and liver diseases. Our competitors may: develop and market product candidates that are less expensive and more effective than our future product candidates; adapt more quickly to new technologies and scientific advances; commercialize competing product candidates before we or our partners can launch any product candidates developed from our product candidates; initiate or withstand substantial price competition more successfully than we can; have greater success in recruiting skilled scientific workers from the limited pool of available talent; more effectively negotiate third party licenses and strategic alliances; and take advantage of acquisition or other opportunities more readily than we can.

Primers for a region of mtDNA proximal to the RIS, within the gene encoding cytchrome b MTCYB ; and a distal region within the gene encoding COX1 MTCO1 ; were used to quantify mtDNA using the primers listed in table 3.1. The ratio of the distal to the proximal mtDNA copy number was then calculated termed mtDNA ratio, see chapter 9. The United States is the world's unrivaled healthcare spending champion . looking at objective statistics, our extra spending does not appear to buy us the most important outcome--better health and prandin. As we mentioned in our previous article about the treatment of Diabetes Mellitus, controlling blood sugar levels is one of the keys to reducing the complications of Diabetes over time. Over the past several years, we have been fortunate that many new treatments have been developed to help control sugar levels. The treatment of Diabetes can be separated into several categories. The first and most important one to reduce the patient's weight and increase exercise. Physicians usually check Body Mass Index BMI ; to help determine weight management needs. A normal BMI is 18.2-25. A BMI range of 2530 is considered overweight and above 30 is obese. Regular exercise also can help control blood sugar levels so that medication can be avoided. Usually physicians will recommend trying to exercise 3 to 5 times a week for 30 minutes, but remember, start exercise programs gradually and with the advice of your physician. If blood sugar levels and HbA1c levels do not reach an adequate level on diet and exercise, then medication is in order. Several medications can help lower the blood sugar levels. Insulin therapy: The types, combinations, and doses of insulin act to help shift glucose sugar ; from the bloodstream into the body's cells so it can be metabolized. This treatment allows the body to replace the insulin it can't make from the pancreas normally. Byetta: This new drug is given by injection also, usually two times a day. It also works by moving glucose into the body's cells so it can be metabolized. Metformin: [Brand names-Glucophage, Glumetza, Fortamet] This oral medication helps restore the body's proper response to the insulin and decreases the amount of sugar that the liver makes and that the stomach and intestines absorb. It can be used alone or in combination with other types of Diabetes medications. Sulfonylurea-type drugs: [Brand names-Glyburide, Diabeta, Glycron, Glynase, Micronase, Amaryl, Glipizide, Glycotrol XL] These stimulate the release of natural insulin from the pancreas and are usually.

A comprehensive toxicology evaluation of the blood specimen obtained during the driver's autopsy was conducted by the Civil Aeromedical Institute CAMI ; , Oklahoma City, Oklahoma, and was negative for tested drugs, including alcohol, cocaine, amphetamines, marijuana, phencyclidine, opiates, benzodiazepines, barbiturates, antidepressants, antihistamines, meprobamate, methaqulaone, and nicotine at established cutoff values.21 Hemoglobin A1c in the specimen, an indication of blood sugar control, was minimally elevated.22 Pickup Driver The pickup driver was 69 years old and had a valid Oklahoma motor vehicle license with an expiration date of August 2004. Her driving record did not include any violations, and her license had no operating restrictions. Her medical records indicated that she was taking prescription medications for several problems, including diabetes treated with Glucophage XR [metformin extended-release] and Glucotrool [glipizide] ; , hypertension treated with Tarka [verapamil trandolapril] ; , and anxiety treated with Triavil [amitriptyline perphenazine] ; . Glucophage XR and Lgucotrol are oral medications for diabetes. Side effects may include abnormally low blood sugar hypoglycemia ; , which can impair performance. Tarka is used to treat high blood pressure. Side effects may include abnormally low blood pressure. Triavil is typically used by patients with moderate to severe anxiety and depression. Amitriptyline, a component of Triavil, has sedative effects. Perphenazine, the other component of Triavil, is an anti-psychotic medication. Triavil may cause tardive dyskinesia, a condition marked by involuntary muscle spasms and twitches in the face and body. According to the driver's medical records, her blood pressure and blood sugar were normal on medications. A comprehensive toxicology evaluation of a blood specimen obtained during her initial medical evaluation after the accident was conducted by the CAMI and was negative for the following drugs: alcohol, cocaine, amphetamines, marijuana, phencyclidine, opiates, benzodiazepines, barbiturates, antidepressants, antihistamines, meprobamate, methaqulaone, and nicotine at established cutoff values. Hemoglobin A1c in the specimen, an indication of blood sugar control, was normal. On May 5, 2001, Safety Board investigators briefly interviewed the driver of the pickup truck in her hospital room. She was asked to describe the events that led up to the accident. She stated that she would not have lost control of her pickup truck if the tractor-trailer had not hit her first. Due to her medical condition and the length of time required for additional questioning, the investigators later followed up with questions about the medications she took and her activities during the 3 to 4 days before the and nizoral. He has received the Saskatchewan Order of Merit 1993 ; and is an Officer of the Order of Canada 1997 ; . Even with those lofty honours, Saskatoon neurologist Dr. Ali Rajput says that receiving the 2006 Physician of the Year Award from the Saskatchewan Medical Association means more to him because it signifies recognition by the people who know and work with him, rather than by a distant committee. Dr. Rajput received the award at the SMA Annual Dinner, held in conjunction with the Spring RA on Friday, May 12 at Temple Gardens in Moose Jaw. As SMA President Dr. Vino Padayachee said, "Dr. Rajput is a leader by example who demonstrates the personal and professional qualities to which we all should aspire. "We developed the Physician of the Year Award to pay tribute to the outstanding contributions made by Saskatchewan physicians to the quality of life in this province, " Dr. Padayachee said. "In Dr. Rajput's case, we also honour a colleague who makes an incredible contribution internationally as well." Born in Pakistan, Dr. Ali Rajput received medical degrees from the University of Sind in that country in 1958 and the University of Michigan in 1966. In 1967 Dr. Rajput moved to Saskatoon to join the staff of the College of Medicine at the University of Saskatchewan. He became an expert in the field of neurology and a Canadian pioneer for research in movement disorders, especially Parkinson's disease. He acquired an international reputation for world-class medical research, attracted funds and scholars to Saskatchewan, and inspired young neurologists to pursue their careers in the province. Frequently consulted by medical researchers worldwide, he has received international acclaim for his work in epidemiology and the treatment of Parkinson's disease. He is also involved in numerous volunteer organizations and was awarded the Morton Schulman Award for Advocacy by the Parkinson's Society in 2001. Dr. Rajput received a commemorative award and an original soapstone sculpture by noted Saskatchewan artist Darren Gowan at the ceremony.
Apgar score 7 at 1 minute: 47 239 QUALITY SCORE: Reference standard: + 20% ; Randomized: 2 ; Apgar score 7 at 5 minutes: 6 239 Method of randomization: NA Verification bias: 3% ; Test reliability variability: Gestational age: + 3 ; Meconium staining: 99 239 41% ; Dating criteria: Other risk factors absent: 4 ; Meconium aspiration: 19 239 8% ; Similar to likely pt pop: + 5 ; Macrosomia birthweight 4000 g ; : Testing protocol described: + Sample size: 52 239 22% ; Statistical tests: 6 ; Post-maturity syndrome: 40 239 Same patient population as 17% ; Phelan, Platt, Yeh, et al. 1985, below. 7 ; C-sections: Overall: 42 239 18% ; For fetal distress: 13 239 5 and diflucan.
ACCUCHECK METERS ACCUCHECK TEST STRIPS ACCUPRIL ACCURETIC ACCUTANE ACTIMMUNE ADVAIR ALESSE # ALFERON N * ALKERAN All Prenatal Vitamins are Preferred. ALLEGRA 30MG, 60mg ALTACE ALOMIDE ALPHAGAN ALREX ALUPENT MDI COMP AMARYL AQUASOL A ARICEPT ARISTOCORT 4mg tab ARISTOCORT 2mg 5ml syrup ASACOL ASTELIN ATROPINE CMPD AUGMENTIN AVANDIA AVC VAGINAL AVITA # * AVONEX AZULFIDINE EN-TAB BACTROBAN CREAM BECLOVENT BENADRYL prescription only ; BENTYL 10mg ml inj BETAPACE BETASERON BRETHAIRE CAFERGOT CALCIFEROL CARNITOR 1, 000gm 5ml inj CARNITOR 330mg tab CATAPRES-TTS CEENU CEFTIN CELONTIN CHEMET CILOXAN CIPRO CLARITIN tabs and reditabs ; CLIMARA COLAZAL COLCHICINE 0.5mg tab COLESTID COLYTE COMBIVIR COMPAZINE SUPPOSITORY COMPAZINE SYRUP CONDYLOX COPAXONE COREG CORTEF 10mg 5ml oral susp CORTIFOAM CORTISPORIN 1.5% opht drops COZAAR CRIXIVAN CYCLOGYL CYTADREN CYTOTEC CYTOXAN DANTRIUM DAPSONE DARVOCET-N 50 DDAVP * DELTASONE 2.5mg tab DENAVIR DEPAKOTE DESOXYN * DEXEDRINE DIASTAT DIBENZYLINE DIDRONEL DIFLUCAN 150mg TAB * DIOVAN DIOVAN HCT DIPROLENE DIPROLENE AF CREAM DIPROSONE 0.1% top spray DOLOPHINE HCL DRYSOL DURAGESIC DYCLONE DYNAPEN EFFEXOR and - XR EFUDEX ELDEPRYL EMCYT EPIPEN JR. 0.15mg inj EPIVIR 10mg ml soln EPIVIR 150mg tab ERGAMISOL ERGOMAR ERYPED ERY-TAB 500mg e.c. tab ESKALITH ESTRADERM ESTRING ETHMOZINE EULEXIN EURAX FAMVIR FELBATOL FLORINEF ACETATE FLONASE FLUDARA Fml LIQUIFILM FML-FORTE OPHTH FOLVITE FOSAMAX FULVICIN P G 125mg, 165mg tab GABITRIL GLUCAGON EMERGENCY KIT GLUCOTROL XL GRANULEX GRIFULVIN V 125mg 5ml oral susp HELIDAC HEPARIN HEXALEN HIVID HMS LIQUIFILM HUMALOG HUMULIN 50 HUMULIN 70 30 HUMULIN L HUMULIN N HUMULIN R HUMULIN U HYZAAR IMITREX inj, nasal spray INFERGEN INFLAMASE and -FORTE INTRON A IOPIDINE ISMELIN SULFATE ISOPTO ATROPINE ISOPTO HOMATROPINE KALETRA KERALYT K-LYTE DS 50meq ; LAC-HYDRIN 12% ; LAMICTAL LAMISIL * LAMPRENE LANTUS LEUKERAN LEUKINE LEVAQUIN LEVOTHYROXINE LIPITOR LIQUID PRED LITHIUM CITRATE LODOSYN LO OVRAL LOPRESSOR HCT LOTEMAX LOTENSIN LOTENSIN HCT LOTREL.
Termination, length of service and certain other factors. If the termination is involuntary or caused by death, the employees are entitled to greater payments than in the case of voluntary termination. The Company had contributory trusteed pension plan which funds a portion of the Company's retirement benefits. The contributory funded defined benefit pension plan, which was established under the Japanese Welfare Pension Insurance Law, covered a substitutional portion of the governmental pension program managed by the Company on behalf of the government and a corporate portion established at the discretion of the Company. In accordance with the Defined Benefit Pension Plan Law enacted in April 2002, the Company applied for transfer of the substitutional portion of past pension obligations to the government and obtained approval by the Ministry of Health, Labor and Welfare on April 1, 2004. Based upon the above and bactroban.

Brand name generic name accupril quinapril hydrochloride tablets accuretic quinapril hcl hydrochlorothiazide tablets aldactazide spironolactone and hydrochlorothiazide tablets aldactone spironolactone tablets amphocin amphotericin b for injection antivert meclizine hcl aricept donepezil hydrochloride tablets aromasin exemestane tablets arthrotec diclofenac sodium and misoprostol tablets atgam lymphocyte immune globulin, anti-thymocyte globulin sterile solution azulfidine sulfasalazine tablets azulfidine en-tabs quinapril hydrochloride tablets bacitracin for injection benadryl diphenhydramine hydrochloride injection caduet amlodipine besylate atorvastatin calcium calan verapamil hydrochloride tablets calan sr verapamil hydrochloride sustained-release oral caplets camptosar irinotecan hydrochloride injection cardura doxazosin mesylate cardura xl doxazosin mesilate extended release tablets caverject alprostadil injection - aqueous caverject alprostadil for injection caverject alprostadil for injection - sterile powder caverject impulset dual chamber system alprostadil for injection cefobid sterile cefoperazone celebrex celecoxib celontin methsuximide capsules cerebyx fosphenytoin sodium injection chantix varenicline cleocin clindamycin phosphate vaginal cream cleocin hcl clindamycin hydrochloride capsules cleocin pediatric clindamycin palmitate hydrochloride for oral solution cleocin phosphate clindamycin injection and clindamycin injection in 5% dextrose cleocin t clindamycin phosphate topical solution, topical gel, and topical lotion cleocin vaginal ovules clindamycin phosphate vaginal suppositories colestid micronized colestipol hydrochloride tablets cortef hydrocortisone tablets corvert ibutilide fumarate injection covera-hs verapamil hydrochloride extended-release tablets cyklokapron tranexamic acid tablets and tranexamic acid injection cytotec misoprostol tablets daypro oxaprozin caplets daypro alta oxaprozin potassium depo-estradiol estradiol cypionate injection depo-medrol methylprednisolone acetate injectable suspension depo-provera contraceptive injection medroxyprogesterone acetate injectable suspension depo-subq provera 104 medroxyprogesterone acetate injectable suspension depo-testosterone testosterone cypionate injection detrol tolterodine tartrate tablets detrol la tolterodine tartrate extended release capsules diabinese chlorpropamide didrex benzphetamine hydrochloride tablets diflucan fluconazole dilantin capsules phenytoin sodium dilantin kapseals phenytoin sodium dilantin infatabs phenytoin tablets dilantin-125 phenytoin oral suspension dipentum olsalazine sodium capsules dostinex cabergoline tablets ellence epirubicin hydrochloride injection emcyt estramustine phosphate sodium capsules eraxis anidulafungin for injection estring estradiol vaginal ring exubera insulin human inhalation powder feldene piroxicam flagyl metronidazole tablets flagyl 375 metronidazole capsules flagyl er metronidazole extended - release tablets fragmin dalteparin sodium injection gelfoam plus hemostasis kit absorbable gelatin sponge gelfoam powder absorbable gelatin powder gelfoam sponge absorbable gelatin compressed sponge genotropin somatropin for injection geocillin carbenicillin indanyl sodium geodon ziprasidone hydrochloride glucotrol glipizide glucotrol xl glipizide gits glynase prestab micronized glyburide tablets glyset miglitol tablets halcion triazolam tablets halotestin ciii fluoxymesterone tablets hemabate carboprost tromethamine injection idamycin idarubicin hydrochloride for injection idamycin pfs idarubicin hydrochloride injection inspra eplerenone tablets lincocin lincomycin hydrochloride capsules and lincomycin injection lipitor atorvastatin calcium tablets lomotil diphenoxylate hydrochloride with atropine sulfate lopid gemfibrozil tablets lyrica pregabalin 25, 50, 100, and 300-mg capsules macugen pegaptanib sodium injection marax tablets ephedrine sulfate, theophylline, hydroxyzine hcl marax-df syrup ephedrine sulfate, theophylline, hydroxyzine hcl medrol methylprednisolone tablets micronase glyburide tablets mycobutin rifabutin capsules nardil phenelzine sulfate tablets navane thiothixene capsules navane im thiothixene hydrochloride intramuscular for injection neurontin gabapentin nicotrol ns nicotine nasal spray nicotrol inhaler nicotine inhalation system nitrostat nitroglycerin tablets norpace disopyramide phosphate capsules norpace cr disopyramide phosphate extended-release capsules norvasc amlodipine besylate ogen estropipate tablets orinase diagnostic tolbutamide for injection permapen isoject penicillin g benzathine injectable suspension pfizerpen for injection penicillin g potassium prepidil gel dinoprostone cervical gel procardia nifedipine procardia xl nifedipine gits extended release tablets prostin vr pediatric alprostadil injection provera medroxyprogesterone acetate tablets rebif interferon beta-1a relpax eletriptan hydrobromide rescriptor delavirdine mesylate revatio sildenafil citrate 20mg r-gene 10 arginine hydrochloride injection selzentry maraviroc tablets sinequan doxepin hcl solu-cortef hydrocortisone sodium succinate for injection solu-medrol methylprednisolone sodium succinate for injection somavert pegvisomant for injection spiriva handihaler tiotropium bromide inhalation powder sutent sunitinib malate synarel nafarelin acetate nasal solution tikosyn dofetilide toposar etoposide injection trelstar depot 75mg triptorelin pamoate for injectable suspension trelstar la 1 25 mg triptorelin pamoate for injectable suspension unasyn ampicillin sulbactam urobiotic vantin cefpodoxime proxetil tablets and cefpodoxime proxetil for oral suspension vfend voriconazole viagra sildenafil citrate vibramycin doxycycline hyclate for injection vibramycin doxycycline calcium, doxycycline hyclate, doxycycline monohydrate viracept nelfinavir mesylate vistaril hydroxyzine pamoate xalatan latanoprost ophthalmic solution xanax alprazolam tablets xanax xr alprazolam extended-release tablets zarontin ethosuximide capsules ethosuximide syrup zinecard dexrazoxane for injection zithromax azithromycin zithromax 600mg tablets azithromycin zithromax iv azithromycin zmax azithromycin extended release zoloft sertraline hydrochloride zyvox linezolid injection, linezolid tablets, linezolid for oral suspension access information designed especially for health care professionals including details about pfizer medicines as well as medical information and patient support materials and famvir and Order glucotrol. This committee is comprised of senior officers of the company and reviews Marathon's overall performance with various environmental compliance programs. The company has an Environmental Management Information System EMIS ; to increase the accuracy of data management and improve the timeliness of information availability. EMIS tracks air pollutants, waste streams and energy efficiency opportunities as well as GHG emissions. Link to Executive Compensation The company says that it used "environmental impact measures" in helping to decide upon the 2004 bonus payments it approved for Marathon's executive team!

Capable of lowering blood glucose levels.16 I wrote my first prescription for a sulfonylurea drug for a patient with type 2 diabetes in 1955, and that was an exciting moment. Most such patients were obese and had been treated with insulin. Although we were not yet aware of insulin resistance, type 2 patients required large insulin doses compared to type 1 patients. Where possible, I discontinued insulin and prescribed the new oral agents. However, some patients failed to respond to the oral drugs primary failure ; , while 20% developed secondary failure to respond. In 1970 and 1971, a study by the University Group Diabetes Program UGDP ; 17 questioned the cardiovascular safety of sulfonylureas. Many patients discontinued the tablets and returned to insulin, but further studies refuted the UGDP findings. In my experience, no cardiovascular adverse events occurred, but the FDA placed a generic warning in the package inserts at that time, and it still remains in the 2002 Physicians' Desk Reference.18 The sulfonylurea family--tolbutamide Orinase ; , acetohexamide Dymelor ; , tolazamide Tolinase ; , glipizide Glucotroll ; , glyburide Micronase ; , and chlorpropamide Diabinese ; --were very important therapeutic players. At present, glyburide, chlorpropamide, glipizide, and glimepiride Amaryl ; are safe and effective and regularly prescribed. Like the sulfonylureas, the newer nateglinide Starlix ; and repaglinide Prandin ; are also insulin secretagogues. Biguanides. It is interesting that Elliott P. Joslin, in the 1959 10th edition of his famous textbook, was a bit wary of both the sulfonylureas and biguanides, stating, "It is too early to make any more than a preliminary evaluation of the place of the sulfonylureas or the biguanides in the management of diabetes."19 I began to prescribe phenformin in 1959, although its mechanism of action was not clear. In my hands, it was very useful in obese type 2 diabetic patients because it lowered blood glucose, pro.
3 development departments of the State government by establishing effective working linkages with them. It is not only necessary to have in the S&T Council representatives from the universities, research institutions, development departments and experts from the production and services sectors, from both the Central and State levels, but there is also a need for holding regular meetings of the State S&T Council to discuss policies and formulate programmes and implementation strategies to derive maximum benefits from S&T. While it is important to support location-specific, region-wise science and technology based programmes, they should be judged against the criteria of employment and income generation for integrated holistic development of the less developed regions. The State S&T Councils should be made to play an appropriate role in the implementation of the Mission Mode Programmes identified by the Scientific Departments like DBT, DSIR etc. and also of IMM-2020 during the 10th Plan. The S&T Councils themselves may not be able to implement all the identified programmes. There is a need to identify appropriate Voluntary Organizations to handle some of the programmes as they will be more closely associating themselves with the gross root level masses. Close interaction with them will help in successful implementation of S&T programmes within the State. The States should utilize the latest technological developments for deriving the maximum benefits. For example, under the National Natural Resources Management System NNRMS ; , an enormous amount of remote sensing data would be available. The State S&T Councils may co-ordinate with the concerned user departments in the State and NNRMS NRDMS units to obtain ground truths related to the remotely sensed data, particularly in the important areas of agriculture, forestry, water resources both ground water and surface water ; , mineral deposits, environment etc. With a view to exchange the experiences of the neighbouring States, periodical regional conferences of the S&T Councils may be organized and regional development programmes initiated. DST at the centre should take a lead role in this aspect. Networking of State S&T Councils and Central S&T agencies departments through NICNET will help the disadvantaged States to benefit from the experiences of the other States.
PAPER - Agranulocytosis with Antithyroid Treatment: What is the value of blood count monitoring? 9.1 Professors Park, Weller and Davies declared non-personal non-specific interests in Roche, but this did not debar them from taking part in the proceedings. 9.2 The Committee considered the evidence before them and advised that: 9.2.1 Regular monitoring of FBC in the first three months of therapy with antithyroid drugs is not considered appropriate. 9.2.2 An article in Current Problems in Pharmacovigilance should be prepared to inform precribers of this review. 9.2.3 The British Thyroid Association and the Endocrine Diabetes Committee of the Royal College of Physicians should be made aware of this decision and asked to comment on the article for Current Problems in Pharmacovigilance. [Note: see article in Current Problems in Pharmacovigilance, volume 25, February 1999 - : mca.gov mca csmhome ].
Melicron Xepa soul Pattinson ; n ; Mexan Imeks Pharma ; o ; Pharmaniaga Gliclazide Pharmaniaga ; p ; Sam Chun Dang Glyclazide The Zyfas ; 16 HYOSCINE BUTYLBROMIDE TAB 10mg a ; Buscopan Boehringer Ingelheim ; [O] b ; Buspan Zontron ; c ; Colospan Hovid ; d ; Copan Duopharma ; e ; Dhacopan Drug Houses Aust. ; f ; Fucon Y.S.P. Industries ; g ; Hyomide CCM Pharm and buy prandin.